Aβ binding molecules

Details Aβ binding molecules Aβ binding molecules

2004-02-06

2009-08-18

Kolker, Daniel E. (Department: 1649)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C530S388250

Reexamination Certificate

active

07575747

ABSTRACT:
The present invention encompasses isolated antibodies, or fragments thereof, that are humanized variants of murine antibody 266 which employ complementarity determining regions derived from murine antibody 266. The variant antibodies are useful for treatment or prevention of conditions and diseases associated with Aβ, including Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy, mild cognitive impairment, and the like.

REFERENCES:
patent: 5004697 (1991-04-01), Pardridge
patent: 5278049 (1994-01-01), Baker et al.
patent: 5593846 (1997-01-01), Schenk et al.
patent: 5688651 (1997-11-01), Solomon
patent: 5753624 (1998-05-01), McMichael et al.
patent: 5766846 (1998-06-01), Schlossmacher et al.
patent: 5837672 (1998-11-01), Schenk et al.
patent: 5851996 (1998-12-01), Kline
patent: 5935927 (1999-08-01), Vitek et al.
patent: 6114113 (2000-09-01), McLaughlin-Taylor et al.
patent: 6114133 (2000-09-01), Seubert et al.
patent: 6218506 (2001-04-01), Krafft et al.
patent: 6284221 (2001-09-01), Schenk et al.
patent: 6582945 (2003-06-01), Raso
patent: 2002/0009445 (2002-01-01), Du et al.
patent: 2002/0058267 (2002-05-01), Ozenberger et al.
patent: 2002/0086847 (2002-07-01), Chain
patent: 2002/0102261 (2002-08-01), Raso
patent: 2002/0136718 (2002-09-01), Raso
patent: 2004/0043418 (2004-03-01), Holtzman et al.
patent: 2004/0192893 (2004-09-01), Stavrianopoulos et al.
patent: 2004/0241164 (2004-12-01), Bales et al.
patent: 2004/0248197 (2004-12-01), Holtzman et al.
patent: 2004/0265308 (2004-12-01), Schenk
patent: 2005/0019330 (2005-01-01), Schenk
patent: 0613007 (1994-02-01), None
patent: 0557270 (1995-05-01), None
patent: 1 257 584 (2001-02-01), None
patent: WO 89/01343 (1989-02-01), None
patent: WO 96/18900 (1996-06-01), None
patent: WO 96/25435 (1996-08-01), None
patent: WO 98/33815 (1998-08-01), None
patent: WO 98/34643 (1998-08-01), None
patent: WO 98/44955 (1998-10-01), None
patent: WO 99/27944 (1999-06-01), None
patent: WO 99/06066 (1999-11-01), None
patent: WO 99/60024 (1999-11-01), None
patent: WO 00/72876 (2000-12-01), None
patent: WO 00/72880 (2000-12-01), None
patent: WO 00/77178 (2000-12-01), None
patent: WO 01/10900 (2001-02-01), None
patent: WO 01/18169 (2001-03-01), None
patent: WO 01/62801 (2001-08-01), None
patent: WO 02/21141 (2002-03-01), None
patent: WO 02/46237 (2002-06-01), None
patent: WO 02/060481 (2002-08-01), None
patent: WO 03/015617 (2003-02-01), None
patent: WO 03/015691 (2003-02-01), None
patent: WO 03/016466 (2003-02-01), None
patent: WO 03/016467 (2003-02-01), None
patent: WO 03/090772 (2003-11-01), None
Paul W. E. Fundamental Immunology, 3rd edition, 1993, pp. 292-295.
Rudikoff et al. Single amino acid substitution altering antigen-binding specificity. Proc Natl Acad Sci U S A. Mar. 1982;79(6):1979-83.
Haass C., et al., “Amyloid beta-peptide is produced by cultured cells during normal metabolism,”Nature,359:322-325 (1992).
Ghiso J., et al., “Epitope map of two polyclonal antibodies that recognize amyloid lesions in patients with Alzheimers disease,” Biochem J, 282 (Pt 2):517-522 (1992).
Seubert P., et al., “Isolation and quantification of soluble Alzheimer's β peptide from biological fluids,”Nature,359:325-327 (1992).
Gaskin F., et al., “Human antibodies reactive with beta-amyloid protein in Alzheimer's disease,”J Exp Med,177(4):1181-1186 (1993).
Flood JF et al., “An amyloid β-protein fragment, Aβ [12-28], equipotently impairs post-training memory processing when injected into different limbic system structures,”Brain Res,663(2):271-276 (1994).
Koudinov A., et al., “The soluble form of Alzheimer's amyloid beta protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma,”Biochem&Biophysic Res Comm,205:1164-1171 (1994).
Schwarzman AL et al., “Transthyretin sequesters amyloid β protein and prevents amyloid formation,”Proc Natl Acad Sci,91:8368-8372, (1994).
Tabaton M., et al., “Soluble amyloid β-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid,”Biochem and Biophysi Res Comm,200(3):1598-1603 (1994).
Walker LC et al., “Labeling of cerebral amyloid in vivo with a monoclonal antibody,”J Neuropathol Exp Neurol,53(4):377-383 (1994).
Wisniewski T., et al., “Alzheimer's disease and soluble A beta,”Neurobiol Aging,15(2):143-52 Review (1994).
DeMattos R.B., et al., “Brain to Plasma Amyloid-β Efflux: a Measure of Brain Amyloid Burden in a Mouse Model of Alzheimer's Disease,” Science, 295, pp. 2264-2267 (2002).
Giulian D., et al., “Specific domains of β-amyloid from Alzheimer plaque elicit neuron killing in human microglia,”J Neurosci,16 (19):6021-6037 (1996).
Hanan E., et al., “Inhibitory effect of monoclonal antibodies on Alzheimer's Bamyloid peptide aggregation,”Int J Exp Clin Invest,3:130-133 (1996).
Solomon B., et al., “Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide,”Proc Natl Acad Sci USA,93(1):452-5 (1996).
Teller JK et al., “Presence of soluble amyloid β-peptide precedes amyloid plaque formation in Down's syndrome,”Nature Medicine,2(1)93-95 (1996).
Tjernberg LO et al., “Arrest of beta-amyloid fibril formation by a pentapeptide ligand,”J Biol Chem,271(15):8545-8548 (1996).
Winter G., et al., “Humanized antibodies”Immunology Today,14(6):243-246 (1996).
Solomon B., et al., “Disaggregation of Alzheimer beta-amyloid by site-directed mAb,”Proc Nat Acad Sci USA,94(8):4109-4112 (1997).
El-Agnaf OM et al., “The influence of the central region containing residues 19- 25 on the aggregation properties and secondary structure of Alzheimer's beta-amyloid peptide,”Eur J Biochem,256(3):560-569 (1998).
He X-Y et al., “Humanization and pharmacokinetics of a monoclonal antibody with specificity for both E- and P- selectin,”J Immunol,160:1029-1035 (1998).
Lambert MP et al., “Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins,”Proc Natl Acad Sci,95:6448-6453 (1998).
Solomon B., et al., The amino terminus of the β-amyloid peptide contains an essential epitode for maintaining its solubility,Progress in Alzheimer's and Parkinson's Diseases,205-211 (1998).
Soto C., et al., “β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications of Alzheimer's therapy,”Nature Medicine,4(7):822-826 (1998).
Blass JP, “Immunologic treatment of Alzheirner's disease,”NEJM,341:1694-1695 (1999).
Kuo YM et al., “High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease,”Biochem Biophys Res Commun,257(3):787-791 (1999).
McLean C., et al., “Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease,”Amer Neurological Assoc,46:860-866 (1999).
Schenk D., et al., “Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse,”Nature,400:173-177 (1999).
St. George-Hyslop P., et al., “Antibody clears senile plaques”Nature,400:116-117 (1999).
Wang J., et al., “The levels of soluble versus insoluble brain Aβ distinguish Alzheimer's disease from normal and pathologic aging,”Experimental Neurology,158:328-337 (1999).
Bard F., et al., “Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce patholgy in a mouse model of Alzheimer disease,”Nat Med,6(8):916-919 (2000).
Games D., et al., “Prevention and reduction of AD-type pathology in PDAPP mice immunized with Aβ1-42,”Annals of NY Acad Sci,920:274-284 (2000).
Levy A., et al., “Immunization for Alzheimer's disease: A shot in the arm or a whiff?”American Neurological

Affiliated with

Also associated with

Rating

Aβ binding molecules does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Aβ binding molecules, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aβ binding molecules will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4080191